Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta
News
Market Highlights: Fed comments scare the market, and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech
Health & Biotech
ASX Biotech Stocks: This brain training app could catch dementia early and Brainchip nabs more patents
News
Market Highlights: US and Euro shares on six-day losing streak, and 5 ASX small caps to watch on Thursday
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
Twiggy’s Tattarang is getting into health tech – which ASX stocks will benefit?
News
Market highlights and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: AdAlta gets patent in India, RhinoMed starts selling in Canada
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ASX Health Stocks: Cannabis biotech Emyria all set for Phase 1 clinical trial of lead CBD drug
Health & Biotech
ASX Health Stocks: MVP’s ‘green whistle’ has finally got to Phase 3 in the US after FDA decision
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
News
ASX Small Cap Lunch Wrap: Who’s taking matters into their own hands today?
Health & Biotech
ASX Health Stocks: Aussie biotechs Argenica and Antisense take major steps in the US
Health & Biotech
ASX Health Stocks: Resapp gets TGA and CE mark approvals for its cough-counting app
News